{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:33:27Z","timestamp":1776814407338,"version":"3.51.2"},"publisher-location":"Berlin, Heidelberg","reference-count":26,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642012211","type":"print"},{"value":"9783642012228","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010]]},"DOI":"10.1007\/978-3-642-01222-8_9","type":"book-chapter","created":{"date-parts":[[2009,11,6]],"date-time":"2009-11-06T04:21:41Z","timestamp":1257481301000},"page":"119-127","source":"Crossref","is-referenced-by-count":23,"title":["Bosutinib"],"prefix":"10.1007","author":[{"given":"Gunhild","family":"Keller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Schafhausen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,10,7]]},"reference":[{"issue":"23","key":"9_CR1_9","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1021\/jm0102250","volume":"44","author":"DH Boschelli","year":"2001","unstructured":"Boschelli DH, Ye F et al (2001) Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem 44(23):3965\u20133977","journal-title":"J Med Chem"},{"issue":"Suppl","key":"9_CR2_9","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1200\/jco.2008.26.15_suppl.7001","volume":"26","author":"TH Bruemmendorf","year":"2008","unstructured":"Bruemmendorf TH, Cervantes F, et al (2008) Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. J Clin Oncol 26(Suppl):abstr. 7001","journal-title":"J Clin Oncol"},{"issue":"1\u20132","key":"9_CR3_9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1615\/CritRevOncog.v7.i1-2.30","volume":"7","author":"SW Chung","year":"1996","unstructured":"Chung SW, Daniel R et al (1996) The ABL genes in normal and abnormal cell development. Crit Rev Oncog 7(1\u20132):33\u201348","journal-title":"Crit Rev Oncog"},{"issue":"4","key":"9_CR4_9","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1158\/0008-5472.CAN-05-2057","volume":"66","author":"AM Coluccia","year":"2006","unstructured":"Coluccia AM, Benati D et al (2006) SKI-606 decreases growth and motility of colorectal \u00adcancer cells by preventing pp 60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res 66(4): 2279\u20132286","journal-title":"Cancer Res"},{"issue":"2","key":"9_CR5_9","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1182\/blood.V101.2.690","volume":"101","author":"NJ Donato","year":"2003","unstructured":"Donato NJ, Wu JY et al (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101(2):690\u2013698","journal-title":"Blood"},{"key":"9_CR6_9","doi-asserted-by":"crossref","unstructured":"Gambacorti-Passerini C, Kantarjian HM, et al (2008) Activity and tolerance of bosutinib in patients with AP and BP CML and Ph+ ALL. J Clin Oncol 26 May 20 (Suppl):abstr. 7049","DOI":"10.1200\/jco.2008.26.15_suppl.7049"},{"issue":"2","key":"9_CR7_9","first-page":"375","volume":"63","author":"JM Golas","year":"2003","unstructured":"Golas JM, Arndt K et al (2003) SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 63(2):375\u2013381","journal-title":"Cancer Res"},{"issue":"12","key":"9_CR8_9","doi-asserted-by":"publisher","first-page":"5358","DOI":"10.1158\/0008-5472.CAN-04-2484","volume":"65","author":"JM Golas","year":"2005","unstructured":"Golas JM, Lucas J et al (2005) SKI-606, a Src\/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res 65(12):5358\u20135364","journal-title":"Cancer Res"},{"issue":"45","key":"9_CR9_9","doi-asserted-by":"publisher","first-page":"16870","DOI":"10.1073\/pnas.0606509103","volume":"103","author":"Y Hu","year":"2006","unstructured":"Hu Y, Swerdlow S et al (2006) Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A 103(45):16870\u201316875","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"9_CR10_9","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1158\/0008-5472.CAN-06-2027","volume":"67","author":"H Jallal","year":"2007","unstructured":"Jallal H, Valentino ML et al (2007) A Src\/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 67(4):1580\u20131588","journal-title":"Cancer Res"},{"issue":"6","key":"9_CR11_9","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2174\/187152007784111278","volume":"7","author":"FM Johnson","year":"2007","unstructured":"Johnson FM, Gallick GE (2007) SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem 7(6):651\u2013659","journal-title":"Anticancer Agents Med Chem"},{"issue":"4","key":"9_CR12_9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1006\/smim.1995.0030","volume":"7","author":"P Laneuville","year":"1995","unstructured":"Laneuville P (1995) Abl tyrosine protein kinase. Semin Immunol 7(4):255\u2013266","journal-title":"Semin Immunol"},{"issue":"1","key":"9_CR13_9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/10428190701713689","volume":"49","author":"S Li","year":"2008","unstructured":"Li S (2008) Src-family kinases in the development and therapy of Philadelphia chromosome-\u00adpositive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma 49(1): 19\u201326","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"9_CR14_9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1006\/bbrc.1997.8043","volume":"243","author":"MP Lutz","year":"1998","unstructured":"Lutz MP, Esser IB et al (1998) Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 243(2):503\u2013508","journal-title":"Biochem Biophys Res Commun"},{"issue":"2\u20133","key":"9_CR15_9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S0959-8049(05)80056-5","volume":"28","author":"NN Mazurenko","year":"1992","unstructured":"Mazurenko NN, Kogan EA et al (1992) Expression of pp 60c-src in human small cell and non-small cell lung carcinomas. Eur J Cancer 28(2\u20133): 372\u2013377","journal-title":"Eur J Cancer"},{"key":"9_CR16_9","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.12.2960","volume":"25","author":"WA Messersmith","year":"2007","unstructured":"Messersmith WA, Krishnamurthi S, Hewes BA, Zacharchuk CM, Abbas R, Martins P, Dowling E, Volkert A, Martin E, Daud AI (2007) Bosutinib (SKI-606), a dual Src\/Abl tyrosine kinase inhibitor: preliminary results from a phase 1 study in patients with advanced malignant solid tumors. J Clin Oncol 25:abstr. 3552","journal-title":"J Clin Oncol"},{"issue":"17","key":"9_CR17_9","first-page":"4773","volume":"52","author":"AE Ottenhoff-Kalff","year":"1992","unstructured":"Ottenhoff-Kalff AE, Rijksen G et al (1992) Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res 52(17):4773\u20134778","journal-title":"Cancer Res"},{"issue":"2","key":"9_CR18_9","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S0955-0674(96)80063-9","volume":"8","author":"AM Pendergast","year":"1996","unstructured":"Pendergast AM (1996) Nuclear tyrosine kinases: from Abl to WEE1. Curr Opin Cell Biol 8(2): 174\u2013181","journal-title":"Curr Opin Cell Biol"},{"issue":"11","key":"9_CR19_9","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/nm1127","volume":"10","author":"A Ptasznik","year":"2004","unstructured":"Ptasznik A, Nakata Y et al (2004) Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 10(11): 1187\u20131189","journal-title":"Nat Med"},{"issue":"23","key":"9_CR20_9","doi-asserted-by":"publisher","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","volume":"66","author":"M Puttini","year":"2006","unstructured":"Puttini M, Coluccia AM et al (2006) In vitro and in vivo activity of SKI-606, a novel Src-Abl \u00adinhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 66(23): 11314\u201311322","journal-title":"Cancer Res"},{"issue":"2 Suppl 2","key":"9_CR21_9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/shem.2003.50034","volume":"40","author":"M Sattler","year":"2003","unstructured":"Sattler M, Griffin JD (2003) Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 40(2 Suppl 2):4\u201310","journal-title":"Semin Hematol"},{"issue":"4","key":"9_CR22_9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1023\/A:1023772912750","volume":"22","author":"JM Summy","year":"2003","unstructured":"Summy JM, Gallick GE (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22(4):337\u2013358","journal-title":"Cancer Metastasis Rev"},{"key":"9_CR23_9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1146\/annurev.cellbio.13.1.513","volume":"13","author":"SM Thomas","year":"1997","unstructured":"Thomas SM, Brugge JS (1997) Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13:513\u2013609","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"4","key":"9_CR24_9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N","volume":"180","author":"BS Verbeek","year":"1996","unstructured":"Verbeek BS, Vroom TM et al (1996) c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 180(4):383\u2013388","journal-title":"J Pathol"},{"issue":"5","key":"9_CR25_9","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1158\/1535-7163.MCT-08-0126","volume":"7","author":"A Vultur","year":"2008","unstructured":"Vultur A, Buettner R et al (2008) SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther 7(5):1185\u20131194","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"9_CR26_9","doi-asserted-by":"publisher","first-page":"366","DOI":"10.2353\/ajpath.2007.060706","volume":"170","author":"J Zhang","year":"2007","unstructured":"Zhang J, Kalyankrishna S et al (2007) SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 170(1):366\u2013376","journal-title":"Am J Pathol"}],"container-title":["Recent Results in Cancer Research","Small Molecules in Oncology"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-01222-8_9.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T05:59:36Z","timestamp":1619762376000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-642-01222-8_9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,7]]},"ISBN":["9783642012211","9783642012228"],"references-count":26,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-01222-8_9","relation":{},"ISSN":["0080-0015"],"issn-type":[{"value":"0080-0015","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10,7]]}}}